Formulation and investigation of 5-FU nanoparticles with factorial design-based studies.
暂无分享,去创建一个
[1] K. P. Rao,et al. Release characteristics of bleomycin mitomycin C and 5-fluorouracil from gelatin microspheres , 1989 .
[2] C Vigneron,et al. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[3] E. Schacht,et al. Polymeric prodrugs of 5-fluorouracil , 1997 .
[4] M. Ercan,et al. Microspheres of 5-fluorouracil using poly(dl-lactic acid): in vitro release properties and distribution in mice after i.v. administration , 1994 .
[5] A. Florence,et al. The Nature of the Oil Phase and the Release of Solutes from Multiple (w/o/w) Emulsions , 1986, The Journal of pharmacy and pharmacology.
[6] Lisbeth Illum,et al. Preparation of Biodegradable, Surface Engineered PLGA Nanospheres with Enhanced Lymphatic Drainage and Lymph Node Uptake , 1997, Pharmaceutical Research.
[7] P. Couvreur,et al. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading , 1990 .
[8] M. Hashida,et al. Evaluation of water in oil and microsphere in oil emulsions as a specific delivery system of 5-fluorouracil into lymphatics. , 1977, Chemical & pharmaceutical bulletin.
[9] A. Bozkır,et al. Chitosan Nanoparticles for Plasmid DNA Delivery: Effect of Chitosan Molecular Structure on Formulation and Release Characteristics , 2004, Drug delivery.
[10] O. Güven,et al. In vitro and in vivo evaluation of PLAGA (50/50) microspheres containing 5-fluorouracil prepared by a solvent evaporation method , 1996 .
[11] A. Florence,et al. Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency , 1990, The Journal of pharmacy and pharmacology.
[12] T. Fujita,et al. Potential for lymphatic targeting of peptides , 1997 .
[13] M. Morishita,et al. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. , 1999, Drug development and industrial pharmacy.
[14] T. Gray,et al. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes , 1994, FEBS letters.
[15] Hideyoshi Harashima,et al. Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes , 1994, Pharmaceutical Research.
[16] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[17] A. Coombes,et al. The preparation of sub-200 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery , 1993 .
[18] Simon Benita,et al. The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design , 1995 .
[19] María J. Alonso,et al. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres , 1997 .
[20] T. Saito,et al. Selective delivery of pepleomycin to esophageal lymph nodes by activated carbon particles. , 1993, Anticancer research.
[21] A. Hagiwara,et al. Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases. , 1986, Anticancer research.
[22] T. Park,et al. Biodegradable Nanoparticles Containing Doxorubicin-PLGA Conjugate for Sustained Release , 1999, Pharmaceutical Research.
[23] M. Hashida,et al. Studies on pharmaceutical modification of anticancer agents. II. Enhanced delivery of bleomycin into lymph by emulsions and drying emulsions. , 1975, Chemical & pharmaceutical bulletin.